Vol. 5 No. 1 (2025)
Reimbursement Reviews

Cariprazine (Vraylar)

decorative image of the issue cover

Published January 16, 2025

Key Messages

  • Reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class.
  • The assessments inform nonbinding recommendations that help guide the reimbursement decisions of Canada’s federal, provincial, and territorial governments, with the exception of Quebec.
  • This review assesses cariprazine (Vraylar); 1.5 mg, 3 mg, 4.5 mg, 6 mg oral capsules.
  • Indication: Vraylar (cariprazine) is indicated for the treatment of schizophrenia in adults.